Benzinga | Dec 8, 2021 10:25AM EST

Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $154

Oppenheimer analyst Jay Olson maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $140 to $154.